Assessment of Alcohol and Other Substance Use in Patients With Chronic Liver Disease
- Read more about Assessment of Alcohol and Other Substance Use in Patients With Chronic Liver Disease
Rachel L. Bachrach, Shari S. Rogal – 22 May 2022
Donor eligibility criteria and liver graft acceptance criteria during normothermic regional perfusion: A systematic review
Ivo J. Schurink, Fenna E. M. Leemkolk, Constantino Fondevila, Riccardo De Carlis, Eric Savier, Gabriel C. Oniscu, Volkert A. L. Huurman, Jeroen Jonge – 22 May 2022 – Acceptance of liver grafts from donations after circulatory death (DCD) largely remains a “black box,” particularly due to the unpredictability of the agonal phase. Abdominal normothermic regional perfusion (aNRP) can reverse ischemic injury early during the procurement procedure, and it simultaneously enables graft viability testing to unravel this black box.
PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference
Andrew M. Shearer, Yanling Wang, Elizabeth K. Fletcher, Rajashree Rana, Emily S. Michael, Nga Nguyen, Manal F. Abdelmalek, Lidija Covic, Athan Kuliopulos – 22 May 2022
Pediatric Autoimmune Liver Disease
Henry C. Lin – 22 May 2022
Eliminating METTL1‐mediated accumulation of PMN‐MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation
Xuezhen Zeng, Guanrui Liao, Shumin Li, Haining Liu, Xiao Zhao, Shuang Li, Kai Lei, Shenghua Zhu, Zhihang Chen, Yi Zhao, Xuxin Ren, Tianhong Su, Alfred Sze‐Lok Cheng, Sui Peng, Shuibin Lin, Ji Wang, Shuling Chen, Ming Kuang – 21 May 2022
Alcohol-Associated Liver Disease
This special interest group aims to help patients with alcohol-associated liver disease through education and research that can drive advances in patient care and government and healthcare.
Acute On Chronic Liver Failure
The mission of the Acute on Chronic Liver Failure SIG is to promote increased understanding of the changing landscape of research into patients with chronic liver disease and cirrhosis who develop acute deterioration of their condition. Through consortia and multi-center studies, the definition, prognostication and therapeutic strategies of acute-on-chronic liver failure are explored.
The overall goal is to generate interest and encourage continuing research into this fast-increasing condition.
Liver Cell Biology In Hepatic Diseases
The mission of the Liver Cell Biology in Hepatic Diseases SIG is to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care.
Liver Fibrosis and Cirrhosis
The Liver Fibrosis and Cirrhosis SIG is an interactive group of investigators focusing on the pathogenesis, diagnosis and treatment of liver fibrosis and outcomes research. This SIG aims to broaden our knowledge of the disease and foster collaborations in basic and translational/clinical studies of liver fibrosis and cirrhosis with a strong focus on extracellular matrix and hepatic stellate cell biology, as well as antifibrotic treatments and trials.
Metabolic Dysfunction-associated Steatotic Liver Disease
The central purpose of the Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) SIG (formerly the NAFLD SIG) is to provide a forum to share ideas, foster collaboration and brainstorm together as an academy of basic and translational investigators. Our mission is to study the pathogenesis, diagnosis, natural history and development of therapeutics for metabolic dysfunction-associated steatotic Liver disease. The MASLD SIG sponsors programs at the AASLD Annual Meeting, identifies emerging topics in MASLD, and supports the educational mission of AASLD policy.